These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36894324)

  • 1. AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production.
    Fujii T; Matsuda Y; Seki T; Shikida N; Iwai Y; Ooba Y; Takahashi K; Isokawa M; Kawaguchi S; Hatada N; Watanabe T; Takasugi R; Nakayama A; Shimbo K; Mendelsohn BA; Okuzumi T; Yamada K
    Bioconjug Chem; 2023 Mar; 34(4):728-38. PubMed ID: 36894324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates.
    Matsuda Y; Seki T; Yamada K; Ooba Y; Takahashi K; Fujii T; Kawaguchi S; Narita T; Nakayama A; Kitahara Y; Mendelsohn BA; Okuzumi T
    Mol Pharm; 2021 Nov; 18(11):4058-4066. PubMed ID: 34579528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AJICAP-M: Traceless Affinity Peptide Mediated Conjugation Technology for Site-Selective Antibody-Drug Conjugate Synthesis.
    Matsuda Y; Shikida N; Hatada N; Yamada K; Seki T; Nakahara Y; Endo Y; Shimbo K; Takahashi K; Nakayama A; Mendelsohn BA; Fujii T; Okuzumi T; Hirasawa S
    Org Lett; 2024 Jul; 26(27):5597-5601. PubMed ID: 38639400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation.
    Matsuda Y; Malinao MC; Robles V; Song J; Yamada K; Mendelsohn BA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Mar; 1140():121981. PubMed ID: 32036254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Good Manufacturing Practice Strategy for Antibody-Drug Conjugate Synthesis Using Site-Specific Chemical Conjugation: First-Generation AJICAP.
    Matsuda Y; Clancy C; Tawfiq Z; Robles V; Mendelsohn BA
    ACS Omega; 2019 Dec; 4(24):20564-20570. PubMed ID: 31858041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Analytical Methods for Antibody-Drug Conjugates Produced by Chemical Site-Specific Conjugation: First-Generation AJICAP.
    Matsuda Y; Robles V; Malinao MC; Song J; Mendelsohn BA
    Anal Chem; 2019 Oct; 91(20):12724-12732. PubMed ID: 31478640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological Evaluation of Maytansinoid-Based Site-Specific Antibody-Drug Conjugate Produced by Fully Chemical Conjugation Approach: AJICAP®.
    Seki T; Yamada K; Ooba Y; Fujii T; Narita T; Nakayama A; Kitahara Y; Mendelsohn BA; Matsuda Y; Okuzumi T
    Front Biosci (Landmark Ed); 2022 Aug; 27(8):234. PubMed ID: 36042175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromatographic analysis of site-specific antibody-drug conjugates produced by AJICAP first-generation technology using a recombinant FcγIIIa receptor-ligand affinity column.
    Matsuda Y; Chakrabarti A; Takahashi K; Yamada K; Nakata K; Okuzumi T; Mendelsohn BA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jul; 1177():122753. PubMed ID: 34098178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Native Ion Exchange Mass Spectrometry to Intact and Subunit Analysis of Site-Specific Antibody-Drug Conjugates Produced by AJICAP First Generation Technology.
    Matsuda Y; Kliman M; Mendelsohn BA
    J Am Soc Mass Spectrom; 2020 Jul; ():. PubMed ID: 32608232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Purification Strategy Utilizing Hydrophobic Interaction Chromatography to Obtain Homogeneous Species from a Site-Specific Antibody Drug Conjugate Produced by AJICAP™ First Generation.
    Matsuda Y; Leung M; Okuzumi T; Mendelsohn B
    Antibodies (Basel); 2020 May; 9(2):. PubMed ID: 32443479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second-Generation.
    Fujii T; Ito K; Takahashi K; Aoki T; Takasugi R; Seki T; Iwai Y; Watanabe T; Hirama R; Tsumura R; Fuchigami H; Yasunaga M; Matsuda Y
    ACS Med Chem Lett; 2023 Dec; 14(12):1767-1773. PubMed ID: 38116449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of process development for antibody-drug conjugates produced by chemical conjugation technology.
    Matsuda Y; Mendelsohn BA
    Expert Opin Biol Ther; 2021 Jul; 21(7):963-975. PubMed ID: 33141625
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
    Tsuchikama K; An Z
    Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates.
    Wiggins B; Liu-Shin L; Yamaguchi H; Ratnaswamy G
    J Pharm Sci; 2015 Apr; 104(4):1362-72. PubMed ID: 25631158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR; Hell T; Merkel AS; Grawunder U
    PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-specific antibody drug conjugates for cancer therapy.
    Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
    MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability.
    Sussman D; Westendorf L; Meyer DW; Leiske CI; Anderson M; Okeley NM; Alley SC; Lyon R; Sanderson RJ; Carter PJ; Benjamin DR
    Protein Eng Des Sel; 2018 Feb; 31(2):47-54. PubMed ID: 29370435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.